Preterm infants of 0 to 6 hours age with signs of RDS were randomly allocated to two groups according random number list. Intra tracheal Alveofact (Boehringer Ingelheim Pharma, Ingelheim, Germany) 100 mg/kg was administered to one group. The other group was treated with intra tracheal poractantalfa (Curosurf, Chiesi farmaceutici, Italy) at the dose of 200 mg/kg as rescue therapy. The RDS diagnosis was based on the classic symptoms including need for a fraction of inspired oxygen (FiO2) more than 30% to maintain oxygen saturation above 90%, tachypnea, retraction and grunting; and was confirmed by characteristic radiologic pattern which include reduced air content and reticulo-granular pattern of lungs with air bronchogram. Early initiation of nasal continuous positive airway pressure (NCPAP) immediately after birth is one of the main principles for the treatment of RDS in our hospital. The other main principle is surfactant administration via endotracheal tube with a brief period of ventilation and subsequent extubation and using NCPAP thereafter. This method is referred as INSURE (INtubation, SURfactant, Extubation) which was first described by verder et al. (14) . The additional dose of surfactant was administered 12 hours later if the infant still required a FiO2 more than 0.40. Primary outcome was remaining on ventilator support through 7 days of age. Secondary outcome was mortality rate, duration of oxygen dependency and hospitalization days in studied patients. Bronchopulmonary dysplasia (BPD) was defined as oxygen depending at day 28. The severity of BPD was determined based on FiO2 requirement at 36 weeks post menstrual age. Cranial ultrasound examination was performed at days 5-7 for diagnosis of intra-ventricular hemorrhage by a pediatric radiologist. Pneumothorax was defined as radiologic evidence of air leak that collected in pleural space. Diagnosis of sepsis was based on presence of clinical signs of sepsis accompanied by positive blood culture. Patent ductus arteriosus (PDA) was diagnosed based on clinical signs and confirmed by echocardiography which was done by an expert pediatric cardiologist. Statistical analyses were performed using the statistical package for social sciences (SPSS) version 16.0. Quantitative data were presented as mean±standard deviation (SD) and qualitative data as frequency and percent. Independent t-test were used for testing continuous scale data and chi square or Fisher exact test for categorical data. A p value less than 0.05 was considered statistically significant.
Results
Of the 183 preterm infants receiving surfactant during the one year study period in our hospital, 53 were excluded from the study because of their age at first surfactant administration above 6 hours (23 infants), Apgar score less than 4 at 5 minutes (15 infants), major congenital anomalies (5 patients), refer to other hospital (4 patients); and parent refuse to consent (6 infants). One hundred thirty neonates with mean gestation age of 28.87±2.21 week and birth weight of 1359±526 gram were enrolled in the study. Sixty six neonates treated with Curosurf and 64 infants received Alveofact. The mean age of infants at surfactant replacement therapy was 5.16±0.66 hours. 
Discussion
In our study, infants who were treated with Alveofact had significantly more re-dosing surfactant and remaining on ventilator support through first week of life. In agree with our study, Proquitte (15) et al. showed that the incidence of bronchopulmonary dysplasia at day 28, IVH, PDA, and pneumothorax were not significantly different between infants treated with Alveofact and Curosurf.
In their study, the course of FiO2, and blood gases were similar in both groups. In our study, infants treated with Alveofact need more respiratory support during first days of hospitalization. Difference in age of infants at first surfactant administration may be clinically and physiologically important. Those infants who received their first surfactant within 3 hour of birth were included in Proquitte study (15) . In the Baroutis study, infants were treated at 4 hour and in our study at mean age 5 hour (8).
However, in one study of 987 infants with 23-30 weeks, gestational ages (16), 244 patients were treated by surfactant administration within first 15 minutes, that considered as prophylaxis and 721 neonates by surfactant administration at 16-180 minutes (defined as early rescue). The rates of re-dosing and mean total doses of surfactant were similar in both groups despite the different ages at surfactant reception. The mortality and complications were also similar. They used natural surfactants in 90% of studied patients, but they didn't compare the results according surfactant type (16) . It is suspected that the subtype of used natural surfactants may affect the clinical responses. Hammoud et al. (17) showed improved oxygenation and reduced ventilator requirements at 5 days after Survanta treatment in comparison with Alveofact treated infants. In a study of newborns with RDS who was treated with natural surfactant, measured interfacial physicchemical parameters in tracheal aspirate samples prove better properties of the surfactant proteins (SP-B and SP-C) containing preparations, including Curosurf and Alveofact (18) . Alveofact showed a higher surface tension lowering capacity under dynamic conditions. On the other hand, it is showed that Curosurf has higher concentrations of plasmalogens and poly unsaturated fatty acid containing phospholipids (PUFA-PL) in comparison with Alveofact. Plasmalogens and PUFA-PL improve the surface properties of lipid mixtures (19) . The incidence of BPD, IVH, sepsis and symptomatic PDA appears unaltered in response to surfactant (20) . The incidence of these complications was similar in Curosurf and Alveofact group in our study. Our findings show some differences in first few days after treatment without significant difference on short term morbidity. The observed difference in ventilator requirements and mortality among patients in our studied patients may be due to lower gestation age and birth weight in Alveofact group, although their difference was not statistically significant with this respect.
Conclusion
In conclusion, the Alveofact receiving infants had more frequency of surfactant replacement therapy, more rate of remaining on ventilator, and longer oxygen supplementation. The rate of bronchopulmonary dysplasia, intraventricular hemorrhage and pneumothorax were similar among patients treated with Curosurf and Alveofact. Future studies with larger number of patients in different range of gestation age and birth weight are recommended to determine superior natural surfactant.
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